Author: Haroon Siddique
‘Index of repression’ includes smears, disinformation and harassment, according to advocacy groupRead More
Ali Omar Karim, 47, who smuggled people via small boats and HGVs, has been jailed for eight years and seven months.Read More
The NEC Group in Birmingham, England, is celebrating 50 years since its opening of the NEC by marking a new chapter in its evolution – bringing its venues andRead More
Situation Report in English on World about Agriculture, Drought, Flood and more; published on 25 Feb 2026 by FEWS NETRead More
Bettendorf Mayor Bob Gallagher highlighted business growth and infrastructure plans during his State of the City address, as businesses expect continued development.Read More
The launch from last week came amid one of Ukraine’s largest long-range attacks into Russia, with Moscow saying it shot down 77 Ukrainian drones.Read More
$1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% year‑over‑year growth Delivered $1.1 billion in operating income in 2025, marking first year of operating profitability VYVGART MG label expansion supported by positive ADAPT SERON and OCULUS results; PDUFA target action date of May 10, 2026 for anti‑AChR antibody‑negative (“seronegative”) gMG Management to host conference call today at 2:30 PM CET (8:30 AM ET) February 26, 2026 7:00 AM CET AmRead More
The city of Sausalito, deeply concerned about maintaining its world-class tourist image and warding off sea level rise, is planning to lure bigger retailers and restaurants without making it like every other place.Read More
Leiden, the Netherlands, February 26, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the fourth quarter and full year 2025 and provide a business update on Thursday, March 12, 2026. Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CET/08:30 am EDT. To participate in the conference call or to watch the live webcast,Read More
Why Corteva’s restructuring plans are in focus Corteva (CTVA) is back on investors’ radar after its recent earnings report, where revenue came in below expectations and management outlined plans to separate the Seed and Crop Chemicals businesses. At the same time, UBS and JPMorgan downgraded the stock, pointing to execution risks around the breakup and a more cautious outlook. This is helping shape how the market is reassessing Corteva’s story right now. See our latest analysis for…Read More